



MKRAWZSENEK@FULBRIGHT.COM
DIRECT DIAL: (512) 536-3020

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

December 1, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING 37 C.F.R. § 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
December 1, 2004 Date	 Michael R. Krawzsenek

RE: *SN 09/941,296 Entitled "FORMULATION OF ADENOVIRUS FOR GENE THERAPY" - Zheng Wu and Shuyuan Zhang*
Our Ref. INRP:067USD1

Commissioner:

Please find enclosed:

1. A Preliminary Amendment and
2. A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/INRP:067USD1.

Sincerely,

Michael R. Krawzsenek
Reg. No. 51,898

MRK/ddr
Encls. As noted
25478339.1/ 10107662




PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Title: FORMULATION OF ADENOVIRUS FOR GENE THERAPY
Appl. No.: 09/941,296
Applicant: Wu *et al.*
Filed: August 28, 2001
TC/A.U.: 1645
Examiner: R. Zeman
Docket No.: INRP:067USD1
Customer No.: 32425
Confirmation No. 6562

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING 37 C.F.R. § 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
December 1, 2004 Date	 Michael R. Krawzsenek

PRELIMINARY AMENDMENT

Sir:

Applicants submit this Preliminary Amendment in the above-referenced case.

Consideration of this case in view of the amendments made below is requested.

Amendments to the Claims are reflected in the listing of claims which begins on page 2.

Remarks begin on page 7 of this paper.